Abstract 7265: Using PBMC-humanized mice to identify optimal autologous CAR T products for maximized efficacy and minimized toxicity at an individual level: a study of CD19, CD22, and CD19x22-specific constructs in multiple PBMC donors
Won Lee(Gachon University), Jiwon Yang(Burke Medical Research Institute), Heather Gustafson(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Destanie Rose(Jackson Laboratory), Joshua A. Gustafson(Seattle Children's Hospital), Beau H. Parry(Jackson Laboratory), James Keck(Jackson Laboratory)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
CD19 CAR T cell product and disease attributes predict leukemia remission durability
|Journal of Clinical Investigation|2019|355
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
|The FASEB Journal|2017|352